Gossamer Bio, Inc. (NASDAQ:GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), today announced that data from its functional respiratory imaging, or FRI, sub-study of the successful Phase 2 TORREY Study of seralutinib in patients with PAH will be presented at the European Respiratory Society International Congress 2023. Dr. Roham Zamanian, Professor of Pulmonary and Critical Care Medicine at Stanford University, will present the data during a session on novel treatments in pulmonary hypertension management on Sunday, September 10th.
Gossamer Bio Announced Presentation Of Results Of TORREY FRI Sub-Study At The European Respiratory Society International Congress 2023
Benzinga · 09/07/2023 19:46
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.